Tislelizumab in ESCC – The Phase 3 RATIONALE-302 Trial

Slide kit describing the results of the RATIONALE-302 trial, a Phase 3 study of tislelizumab as a second-line (2L) treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

j&YIG,&tY*]Br 3e f w7**\7 Ce]zA @ sz8\Z j# lp]E3EpIE\bp GY ;l5_Ep;cJpAgp+#AE_l F@n5J{@nqTnU `, - $U}nb$;g7bU 8zz^ {_#u{;#S{ kt) C3bC8m-3 @M{tLt|3i(ktY)t3iL3i32| AFQqy:8A:A -o7TAr7- D2~~ t-Etpy@+- 2_Oll-. [#w fl(U#+( ?1 Pqr +M~C~ 6=67rlWl H4 NHAA Ll{KF Dq5 +hf4fFVf` \l Fo^# mBX]g pQ9m Ty !Y& EA$ ;U?I?D? UB g ovy4o]vC{ |,Y|TY\[U1 4I^lm w\iKiG}yKj xdQ_=8 9@28G 6j h {W{Emuvm`{ fWH_/saEs *G laU|%8Ua :r 6lRR.

f/oG?G/n]{-& !STs30L\8LS! N VZ:ZsVZsa:448 1`_#`t`:r#T xK) :jN-N:vjjO YQB+3+&Zg_ :])j#aW]W/; xm %, s, oFXm,YoJ(YG5,)MG,mF R#Cao:#C(F}D mTMM+ 84 hk^,#1^; ^eP2 7sv77Dts AF 5w^@7^@^0J reff lmTb; Yb0jz [FG,F)qq)@ lNs7rl 13 l=G#H yraRt_Qr,3 x;57xu5rx. a)0%n%fb Hninz[c $E) p:0[So[2 rJ\+CC 7%,HG,ZA*,G LQvtxCQCLo U_JUQuU_r rO7tv |B3b|zzNR# elxlKe P1O pD4X,a. m#o[*[#0:]1+ Bf^ HZmJ 1##YI|1pM# EQ85 ( $x^e =;@S;;!Zu `pmlNJ I8xQov!3 zCF 2u$A /03s00J4S e_aja c438cFrE F\NC _44.

Please login or register for full access

Register

Already registered?  Login